“Active” grants have been awarded, but have not received final payment. Many Flinn Foundation grants are multi-year awards that receive payments at several junctures. In some cases, grants are extended (without additional funding) because the work has not been completed.
This list is not comprehensive. It excludes modest, miscellaneous awards. However, it represents the Foundation’s project-specific grant-making to achieve its strategic goals.
Search
Technical Development Corporation (TDC)
Amount: $266,000
Award Date: 2024
Duration: 36 months
Program Area: Arts and Culture
Analytic and strategic support and consultation for the Flinn Foundation and its arts-and-culture grantee pool, toward achieving the goals of the Foundation’s Initiative for Financial and Creative Health.
The Phoenix Symphony
Amount: $300,000
Award Date: 2024
Duration: 36 months
Program Area: Arts and Culture
Support for a project advancing organizational goals in the “post-pandemic” period. This grant, awarded under the Foundation’s arts-and-culture Initiative for Financial and Creative Health, will involve close examination of the organization’s capitalization strategies.
Tucson Museum of Art
Amount: $100,000
Award Date: 2024
Duration: 36 months
Program Area: Arts and Culture
Support for a project advancing organizational goals in the “post-pandemic” period. This grant, awarded under the Foundation’s arts-and-culture Initiative for Financial and Creative Health, will involve close examination of the organization’s capitalization strategies.
Tucson Symphony Orchestra
Amount: $300,000
Award Date: 2024
Duration: 36 months
Program Area: Arts and Culture
Support for a project advancing organizational goals in the “post-pandemic” period. This grant, awarded under the Foundation’s arts-and-culture Initiative for Financial and Creative Health, will involve close examination of the organization’s capitalization strategies.
University of Arizona
Amount: $100,000
Award Date: 2026
Duration: 12 months
Program Area: Bioscience
Translational Seed Grant: Follow-on funding to develop diagnostic tools for cardiovascular disease. The team aims to develop a predictive assay for chronic ischemic heart failure, where smarter biomarkers can enable more targeted therapies. Follow-on funds will be used to develop a predictive assay in heart failure patients, filing additional IP for peripheral profiles in the process.
University of Arizona
Amount: $100,000
Award Date: 2026
Duration: 18 months
Program Area: Bioscience
Translational Seed Grant: Endometrial cancer is the most prevalent gynecologic malignancy in the United States and Arizona, with incidence and mortality rates continuing to rise. Current diagnostic procedures, such as dilation and curettage or endometrial biopsy, are invasive, costly, and often inaccessible. The team is developing a non-invasive diagnostic platform leveraging cervicovaginal sampling and biomarker analysis for detection. Their custom multiplex biomarker assay optimized for clinical implementation aims to reduce diagnostic delays and improve outcomes for women.
University of Arizona
Amount: $50,000
Award Date: 2026
Duration: 18 months
Program Area: Bioscience
Currently, the only way to determine if a person has schizophrenia is through a psychiatric evaluation. A major reason that no biomarkers for schizophrenia have been identified is that the organ responsible for the illness, the brain, is not accessible. This team has identified a way to detect abnormal function of genes essential for brain development and function from a blood sample for use in diagnosing schizophrenia.
University of Arizona
Amount: $660,000
Award Date: 2025
Duration: 48 months
Program Area: Flinn Scholars
Scholarship awards for members of the Flinn Scholars Class of 2025.
University of Arizona
Amount: $100,000
Award Date: 2025
Duration: 18 months
Program Area: Bioscience
Translational Seed Grant: Parkinson’s disease is a debilitating neurodegenerative disease and is a growing source of disability and mortality. The therapy developed by this team aims to regenerate affected areas of the brain and treat the underlying cause of PD, which impacts about 1 million Americans. The disease is characterized by progressive loss of motor control but also affects multiple neural systems including sleep, sense of smell, taste, and cognition. The use of allopregnanolone (Allo; a naturally occurring molecule) for the treatment of neurodegenerative diseases including Parkinson’s is being licensed from the University of Arizona. Allo is a neurosteroid, used here because it causes a fast increase of human neural stem cells, or cells that can self-renew and create more cells in the central nervous system.
University of Arizona
Amount: $100,000
Award Date: 2025
Duration: 18 months
Program Area: Bioscience
Translational Seed Grant: Diagnostic tools that enable patient stratification have been effective in cancer treatments. The project aims to develop similar tools for patients with cardiovascular disease where they currently don’t exist. Inflammation and fibrosis result in intractable diseases worldwide, such as chronic ischemic heart failure. The project team has developed tests to determine which patients have significant levels of inflammation, theorizing that they will identify which patients will have a positive benefit if treated with immunomodulatory treatments.